Objective: To assess the incidence of renal injury among pediatric patients who received aprotinin while undergoing cardiac surgery compared with those who received ε-aminocaproic acid (EACA).
Design: A retrospective observational study.
Setting: A single academic center.
Participants: Pediatric cardiac patients who had cardiopulmonary bypass and received aprotinin or EACA.
Intervention: Patients undergoing pediatric cardiac surgery received aprotinin from 2005 to 2007 and EACA from 2008 to 2009.
Measurements And Main Results: The primary outcome was acute kidney injury (AKI) defined as serum Cr elevation at discharge more than 1.5 times the baseline value. Secondary outcomes included bleeding, blood transfusion, and the volume of chest tube drainage in the first 24 hours postoperatively. One hundred seventy-eight patients met inclusion criteria; 120 patients received aprotinin, and 58 patients received EACA. These 2 groups did not differ significantly in age, weight, or duration of cardiac bypass. Logistic regression analysis, adjusted for confounding variables (ie, baseline Cr, sex, age, CPB time, inotropic support and vasopressors), showed a higher odds of suffering AKI at discharge with the usage of aprotinin (odds ratio = 4.7; 95% confidence interval, 1.1-19.5; p = 0.03). The volume of the first 24 hours of chest tube drainage was not significantly different between groups, as well as packed red blood cells and cryoprecipitate units. However, fresh frozen plasma and platelets showed statistically significant differences with more transfusion in the EACA group.
Conclusion: In this retrospective study, the authors observed a higher odds of AKI for aprotinin usage compared with EACA, suggesting that the known concern for adults with adverse kidney effects with aprotinin is also appropriate for pediatric patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2011.01.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aprotinin in high-risk isolated coronary artery bypass graft patients: a 3-year propensity matched study.
J Cardiothorac Surg
July 2024
Department of Cardiothoracic Surgery, Castle Hill Hospital, Hull University Teaching Hospitals Trust, Cottingham, UK.
Background: Aprotinin, a serine protease inhibitor, has been used variably in cardiac surgery amidst ongoing debates about its safety following several previous studies. This study assesses the outcomes of aprotinin in high-risk isolated Coronary Artery Bypass Graft (iCABG) patients.
Methods: The study retrospectively analysed a cohort of 1026 iCABG patients, including 51 patients who underwent aprotinin treatment.
Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee surgery: a systematic review and network meta-analysis.
Cochrane Database Syst Rev
January 2024
Haematology/Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.
Article Synopsis
- Hip and knee replacement surgeries can significantly improve quality of life but carry risks of bleeding, with many patients suffering from anemia before and after the surgery, leading to high rates of blood transfusions.
- The study aims to evaluate the effectiveness of various pharmacological interventions in minimizing blood loss during these surgeries and to determine the best timing, dosage, and method of administration for these treatments.
- A comprehensive search of several medical databases was conducted to gather randomized controlled trials focused on elective hip and knee surgeries, excluding emergency cases and studies that did not follow proper registration protocols.
Use of Aprotinin versus Tranexamic Acid in Cardiac Surgery Patients with High-Risk for Excessive Bleeding (APACHE) trial: a multicentre retrospective comparative non-randomized historical study.
Eur J Cardiothorac Surg
February 2024
Department of Cardiovascular Anaesthesia and Critical Care, CHU Bordeaux, France.
Objectives: Following the reintroduction of aprotinin into the European market, the French Society of Cardiovascular and Thoracic Anaesthesiologists recommended its prophylactic use at half-dose for high-risk cardiac surgery patients. We examined whether the use of aprotinin instead of tranexamic acid could significantly reduce severe perioperative bleeding.
Methods: This multicentre, retrospective, historical study included cardiac surgery patients treated with aprotinin or tranexamic acid between December 2017 and September 2020.
Ulinastatin in combination with aprotinin improves systemic inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass.
Am J Transl Res
November 2023
Department of Cardiovascular Medicine, The First Hospital of Yulin Yulin 718000, Shaanxi, China.
Objective: To investigate the impact of ulinastatin combined with protease inhibitors on serum inflammatory factors in patients undergoing cardiac surgery with cardiopulmonary bypass.
Methods: A retrospective analysis was conducted on 86 patients who underwent cardiac surgery with cardiopulmonary bypass at Xi'an Gaoxin Hospital from May 2019 to June 2021. Based on the administration of drugs by a micro-infusion pump after anesthesia induction and before skin incision, the patients were divided into an observation group (receiving ulinastatin at a dose of 12,000 U/kg and protease inhibitors at a dose of 4 million units) with 46 cases and a control group (receiving protease inhibitors at a dose of 2 million units) with 40 cases.
Simultaneous induction of vasculature and neuronal network formation on a chip reveals a dynamic interrelationship between cell types.
Cell Commun Signal
June 2023
NeuroGroup, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Background: Neuronal networks receive and deliver information to regulate bodily functions while the vascular network provides oxygen, nutrients, and signaling molecules to tissues. Neurovascular interactions are vital for both tissue development and maintaining homeostasis in adulthood; these two network systems align and reciprocally communicate with one another. Although communication between network systems has been acknowledged, the lack of relevant in vitro models has hindered research at the mechanistic level.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!